Back to search

Article

Development of a prediction system for KRAS mutation detection via circulating tumour DNA analysis among patients with unresectable pancreatic cancer

2024-12-18

Abstract excerpt

<title>Abstract</title> <p>Background Pancreatic cancer (PC) is an aggressive malignancy with a poor prognosis and limited treatment options. Advances in molecular profiling and liquid biopsy, specifically the detection of circulating tumour DNA (ctDNA), offer new avenues for personalized therapy. KRAS mutations are present in approximately 63–70% of PC patients, but detection via liquid biopsy can be influenced...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
8187e7fd-e602-5b5b-8ae9-21a9b6ca2fd8
DOI
10.21203/rs.3.rs-5444557/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Development of a prediction system for KRAS mutation detection via circulating tumour DNA analysis among patients with unresectable pancreatic cancerDOI 10.21203/rs.3.rs-5444557/v1
Evaluation of circulating tumor DNA as a biomarker in pancreatic cancer with liver metastasisSemantic proximity
Mutant KRAS Circulating Tumor DNA Is an Accurate Tool for Pancreatic Cancer Monitoring.Semantic proximity
Optimal Value of Mutant KRAS Circulating Tumor DNA for Predicting Prognosis and Monitoring in Patients with Pancreatic Adenocarcinoma: A Prospective Multicenter Cohort Study.Semantic proximity
Identification of KRASG12C Mutations in Circulating Tumor DNA in Patients With Cancer.Semantic proximity
KRAS mutations in blood circulating cell-free DNA: a pancreatic cancer case-control.Semantic proximity
Detection of mutated KRAS, TP53, CDK2A, and SMAD4 in tumor cell-free DNA of Brazilian pancreatic adenocarcinoma patients using next-generation sequencingSemantic proximity
Circulating tumor DNA tracking in patients with pancreatic cancer using next-generation sequencing.Semantic proximity
Evaluation of circulating cell-free KRAS mutational status as a molecular monitoring tool in patients with pancreatic cancer.Semantic proximity
KRAS Mutant Allele Fraction in Circulating Cell-Free DNA Correlates With Clinical Stage in Pancreatic Cancer PatientsSemantic proximity
Cell free DNA in patients with pancreatic adenocarcinoma: clinicopathologic correlationsSemantic proximity
Circulating tumor DNA in unresectable pancreatic cancer is a strong predictor of first-line treatment efficacy: The KRASCIPANC prospective study.Semantic proximity
Cell free DNA in patients with pancreatic adenocarcinoma: clinicopathologic correlations.Semantic proximity
Select a neighboring publication to make it the new centre.